Emmanuelle Malaurie

540 total citations
15 papers, 199 citations indexed

About

Emmanuelle Malaurie is a scholar working on Reproductive Medicine, Oncology and Surgery. According to data from OpenAlex, Emmanuelle Malaurie has authored 15 papers receiving a total of 199 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Reproductive Medicine, 6 papers in Oncology and 5 papers in Surgery. Recurrent topics in Emmanuelle Malaurie's work include Ovarian cancer diagnosis and treatment (7 papers), Drug Transport and Resistance Mechanisms (2 papers) and Bladder and Urothelial Cancer Treatments (2 papers). Emmanuelle Malaurie is often cited by papers focused on Ovarian cancer diagnosis and treatment (7 papers), Drug Transport and Resistance Mechanisms (2 papers) and Bladder and Urothelial Cancer Treatments (2 papers). Emmanuelle Malaurie collaborates with scholars based in France, Switzerland and Italy. Emmanuelle Malaurie's co-authors include Saı̈k Urien, I. Monnet, Nicolas Simon, Jean-Claude Duché, Jérôme Barré, Jean‐Paul Tillement, Éric Dailly, Alain Lortholary, Nicolas Simon and Michel Lemaire and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Emmanuelle Malaurie

14 papers receiving 193 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Emmanuelle Malaurie France 7 78 76 56 38 23 15 199
Robert Dood United States 8 89 1.1× 66 0.9× 63 1.1× 22 0.6× 33 1.4× 20 269
Josef Chovanec Czechia 9 74 0.9× 86 1.1× 90 1.6× 37 1.0× 21 0.9× 23 275
Jozef Višňovský Slovakia 12 152 1.9× 81 1.1× 74 1.3× 30 0.8× 42 1.8× 47 384
J Belotte United States 10 107 1.4× 83 1.1× 78 1.4× 86 2.3× 14 0.6× 19 316
Isabelle Farré France 5 80 1.0× 35 0.5× 62 1.1× 9 0.2× 42 1.8× 10 208
Chunqin Pan China 10 153 2.0× 35 0.5× 22 0.4× 19 0.5× 19 0.8× 14 276
Koji Horie Japan 10 117 1.5× 78 1.0× 79 1.4× 29 0.8× 15 0.7× 16 333
Motonao Nakao Japan 11 143 1.8× 63 0.8× 24 0.4× 102 2.7× 47 2.0× 27 397
Shuangwei Zou China 10 154 2.0× 53 0.7× 29 0.5× 42 1.1× 74 3.2× 20 302

Countries citing papers authored by Emmanuelle Malaurie

Since Specialization
Citations

This map shows the geographic impact of Emmanuelle Malaurie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emmanuelle Malaurie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emmanuelle Malaurie more than expected).

Fields of papers citing papers by Emmanuelle Malaurie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emmanuelle Malaurie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emmanuelle Malaurie. The network helps show where Emmanuelle Malaurie may publish in the future.

Co-authorship network of co-authors of Emmanuelle Malaurie

This figure shows the co-authorship network connecting the top 25 collaborators of Emmanuelle Malaurie. A scholar is included among the top collaborators of Emmanuelle Malaurie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emmanuelle Malaurie. Emmanuelle Malaurie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Léary, Alexandra, Christophe Schneider, Elisa Yaniz‐Galende, et al.. (2023). CD47 expression in ovarian cancer: Dynamic correlation with lymphocyte and macrophage features as well as thrombospondin-1 (TSP-1) under neoadjuvant chemotherapy.. Journal of Clinical Oncology. 41(16_suppl). 5569–5569.
2.
Hélissey, Carole, Charles Parnot, Antoine Schernberg, et al.. (2023). Urinary proteome as a prognostic factor in the deterioration of the quality of life of patients with localized prostate cancer during radiotherapy: Radiotoxicity Bladder Biomarkers (RABBIO) prospective trial.. Journal of Clinical Oncology. 41(6_suppl). 344–344. 1 indexed citations
3.
4.
Blanc‐Durand, Félix, Catherine Genestie, Étienne Rouleau, et al.. (2021). Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study.. Journal of Clinical Oncology. 39(15_suppl). 5513–5513. 10 indexed citations
5.
Falandry, Claire, Frédérique Rousseau, Marie‐Ange Mouret‐Reynier, et al.. (2021). Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer. JAMA Oncology. 7(6). 853–853. 46 indexed citations
6.
Berton-Rigaud, Dominique, Anne Floquet, Agnès Dechartres, et al.. (2019). Use of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC)/ The GINECO ENCOURAGE cohort of 500 French patients. Annals of Oncology. 30. v418–v418. 2 indexed citations
7.
Ferron, Gwénaël, Gaëtan De Rauglaudre, Pierre Combe, et al.. (2019). Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.. Journal of Clinical Oncology. 37(15_suppl). 5512–5512. 11 indexed citations
8.
9.
Tod, Michel, Olivier Colomban, Isabelle Laure Ray-Coquard, et al.. (2019). Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: Data from the randomized CHIVA trial (a GINECO-GCIG study). Annals of Oncology. 30. v783–v784. 1 indexed citations
10.
Dubot, Coraline, Emmanuelle Bourbouloux, Olivier Mir, et al.. (2014). ASTER 70s UNICANCER phase III Trial: Can a genomic prognosticator help tailoring adjuvant systemic treatment for luminal breast carcinoma in elderly women?. Journal of Geriatric Oncology. 5. S28–S28. 1 indexed citations
11.
Vieillefond, Annick, Philippe Beuzeboc, L. Mignot, et al.. (2005). HER2 status in urothelial bladder cancer (UC): screening of patients eligible for a phase II randomized study of gemcitabine plus platinum salt with or without trastuzumab. Journal of Clinical Oncology. 23(16_suppl). 4700–4700. 5 indexed citations
12.
Bois, Andreas du, M. Combe, Justine Rochon, et al.. (2004). Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB–IV. An AGO-GINECO Intergroup phase III trial. Journal of Clinical Oncology. 22(14_suppl). 5007–5007. 13 indexed citations
13.
Duché, Jean-Claude, Saı̈k Urien, Nicolas Simon, et al.. (2000). Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer. Clinical Biochemistry. 33(3). 197–202. 76 indexed citations
14.
Simon, Nicolas, Éric Dailly, Emmanuelle Malaurie, et al.. (1998). Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance‐reversing cyclosporin. British Journal of Clinical Pharmacology. 45(2). 173–175. 20 indexed citations
15.
Khayat, D., et al.. (1992). Phase I study of Datelliptium chloride, hydrochloride given by 24-h continuous intravenous infusion. Cancer Chemotherapy and Pharmacology. 30(3). 226–228. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert Dood Breakdown of academic impact, for papers by Josef Chovanec Breakdown of academic impact, for papers by Jozef Višňovský Breakdown of academic impact, for papers by J Belotte Breakdown of academic impact, for papers by Isabelle Farré Breakdown of academic impact, for papers by Chunqin Pan Breakdown of academic impact, for papers by Koji Horie Breakdown of academic impact, for papers by Motonao Nakao Breakdown of academic impact, for papers by Shuangwei Zou
Rankless by CCL
2026